News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  

2025 LCRF – Boehringer Ingelheim Team Science Award on Innovative Therapeutic Strategies to Understand and Treat Lung Cancers Harboring HER2 Mutations
Jun 27, 2025, 13:52

2025 LCRF – Boehringer Ingelheim Team Science Award on Innovative Therapeutic Strategies to Understand and Treat Lung Cancers Harboring HER2 Mutations

This award supports multidisciplinary teams investigating the biology, resistance mechanisms, and novel treatments for HER2-mutant non–small cell lung cancer (NSCLC). Projects must integrate clinical, basic, and/or translational work around a central theme and may include analyses of real-world datasets, tumor microenvironment studies, biomarker discovery, and exploration of HER2 amplification or overexpression in conjunction with mutations.

Eligibility Criteria

  • Collaborative “team science” proposals with closely integrated projects spanning clinical, basic, and/or translational research

  • Studies in patients with lung cancer harboring HER2 mutations (and related alterations such as amplification/overexpression)

  • Topics may include, but are not limited to:

    • Biology and mechanisms of HER2-driven tumor progression

    • Primary or secondary resistance to targeted, immune, or combination therapies

    • Real-world data analyses correlating patient demographics with mutation status

    • Immune landscape and tumor microenvironment characterization

    • Biomarker identification for therapy sensitivity

    • Optimization of treatment efficacy and tolerability

Funding Details

  • Maximum award: 1,500,000 USD total over 3 years

  • Single application per investigator per grant cycle

Application Process & Deadlines

  • Two-step submission: Letter of Intent (LOI) → Full proposal (invited applicants only)

  • LOI Deadline: July 29, 2025

  • Full Proposal Deadline: November 4, 2025

Further Information

For full RFP details, eligibility criteria, and application instructions, visit the LCRF Grant Application Portal or contact [email protected].

biomarker discovery Boehringer Ingelheim cancer HER2 LCRF Lung cancer NSCLC OncoDaily Oncology real world data Resistance mechanisms Team Science translational research tumor microenvironment
Special Coverage
Career
Jul 9, 2025, 08:22
Call for Applications: Young SIOP Representative for Nutrition Network Steering Group - AIEOP
Opinion
Jul 9, 2025, 08:07
Even after death, bereavement support continues for the patient’s family - ACREOL Global
Blog
Jul 9, 2025, 01:52
Zoë Mullan: Hope to See Some Familiar Faces at 2025 Asian Conference on Implementation Science
Insight
Jul 9, 2025, 01:44
Inhibiting CDS2 Selectively Kills CDS1-deficient Cancer Cells - The Netherlands Cancer Institute
Blog
Jul 8, 2025, 20:46
Experts Driving Innovation in Radiation Oncology Through the ESTRO Focus Group
Blog
Jul 8, 2025, 20:27
Abdu Adem Yesufe: Immensely Grateful for IAEA's Support Thus Far
Blog
Jul 8, 2025, 20:24
Svetlana Nikic: Honored to Attend HBA and Almirall Event on Women’s Development
Blog
Jul 8, 2025, 20:03
Alfredo Addeo: Colloquiums of the Department of Medicine in HUG Presented a Fascinating Conference
Blog
Jul 8, 2025, 19:47
A Webinar on "Overcoming Barriers to Pediatric Cancer Care in Nepal" on July 17 - The Max Foundation
Blog
Jul 8, 2025, 19:34
Edward Cliff: A Short Taster of Our Session to the Video Journal of Hematology and Hematological Oncology
Drugs
Jul 8, 2025, 18:55
Miguel Bronchud: Who Pays for New Drugs?
Blog
Jul 8, 2025, 18:45
Women With Overweight/Obesity and a History of CVD are 31% More Likely to Develop Breast Cancer - IARC